Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
medical devices
10
×
national blog main
10
×
national top stories
new york blog main
new york top stories
10
×
san francisco blog main
san francisco top stories
boston blog main
boston top stories
detroit blog main
detroit top stories
life sciences
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
national
boulder/denver blog main
boulder/denver top stories
fda
indiana blog main
indiana top stories
clinical trials
ipo
novartis
cancer
glaxosmithkline
startups
abbvie
celgene
crispr
deals
eli lilly
What
bio
roundup
life
new
science
biotechs
cancer
companies
days
drugs
investors
ipo
medical
startup
therapeutics
week
years
abbvie’s
acquiring
admits
advantages
ago
ahead
allogene
attributes
august
auris
bails
bar
big
billion
biofourmis
biotech
black
brand
bridgebio
brings
bucks
builds
busy
Language
unset
Current search:
" national blog main "
×
" medical devices "
×
" new york top stories "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Review: Inside the House of Lies at Theranos
@xconomy.com
5 years ago
Johnson & Johnson to Buy Robotics Startup Auris Health for $3.4B
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way